{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:24:39Z","timestamp":1776090279506,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.urolonc.2007.10.016","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T09:13:05Z","timestamp":1202289185000},"page":"616-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience"],"prefix":"10.1016","volume":"26","author":[{"given":"Nayan Kumar","family":"Mohanty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiba L.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawan","family":"Vasudeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender P.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2007.10.016_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.COC.0000026911.98171.C6","article-title":"Impact of Intravesical chemotherapy vs","volume":"26","author":"Huncharek","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical BCG vs. mitomycin-C for superficial bladder cancer, a formal meta-analysis of comparative studies on recurrences and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib4","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.ju.0000066840.42991.4a","article-title":"Intravesical bacillus Calmette-Guerin therapy for Stage T1 Grade III TCC of the bladder: Recurrences, progression, and survival in a study of 57 patients","volume":"169","author":"Peyromaure","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Evans. Intravesical gemcitabine shows promise in intermediate risk superficial bladder cancer","volume":"46","author":"Christopher","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining Bacillus Calmette Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1464-410X.2003.04894.x","article-title":"Superficial Transitional (Ta\/T1\/CIS) cell carcinoma of the bladder","volume":"94","author":"Konety","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2007.10.016_bib8","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1200\/JCO.2003.08.099","article-title":"Intravesical therapy for superficial bladder cancer: slow but steady progress","volume":"21","author":"Lamm","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib9","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib10","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A Phase II study of gemcitabine in patients with TCC of the urinary tract previously treated with platinum","volume":"34","author":"Lorusco","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2007.10.016_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001813-200207000-00002","article-title":"Selective cytotoxicity of gemcitabine in bladder cancer cell lines","volume":"13","author":"Kilani","year":"2002","journal-title":"Anticancer drugs"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2007.10.016_bib12","first-page":"508","article-title":"Studies on gemcitabine as an intravesical agent for superficial bladder cancer","volume":"4","author":"O'Donnell","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib14","doi-asserted-by":"crossref","first-page":"A274","DOI":"10.1016\/S0022-5347(18)37536-0","article-title":"Phase II trial of intravesical gemcitabine in BCG refractory transitional cell carcinoma of the bladder","volume":"171","author":"Dalbagni","year":"2004","journal-title":"J Urol"},{"issue":"14S","key":"10.1016\/j.urolonc.2007.10.016_bib15","first-page":"4601","article-title":"Adjuvant intravesical gemcitabine in intermediate or high risk transitional cell carcinoma (TCC) of the bladder","volume":"22","author":"Bartoletti","year":"2004","journal-title":"JCO"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2007.10.016_bib16","doi-asserted-by":"crossref","first-page":"A4601","DOI":"10.1200\/jco.2004.22.90140.4601","article-title":"Intravesical gemcitabine single agent as adjuvant chemotherapy in superficial TCC of the bladder","volume":"22","author":"Bouzid","year":"2004","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2007.10.016_bib17","doi-asserted-by":"crossref","first-page":"A275","DOI":"10.1016\/S0022-5347(18)37537-2","article-title":"Intravesical administration of gemcitabine in superficial bladder cancer\u2014a Phase I study with pharmaco dynamic evaluation","volume":"171","author":"De Berardinis","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib18","doi-asserted-by":"crossref","first-page":"A272","DOI":"10.1016\/S0022-5347(18)37534-7","article-title":"A Phase I-II study on intravesical gemcitabine in superficial bladder papillary tumors","volume":"171","author":"Serretta","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2007.10.016_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial TCC of the bladder\u2014a Phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907002955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143907002955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:54:55Z","timestamp":1761040495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143907002955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1078143907002955"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.10.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder\u2014our experience","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}